The Nasdaq notification letter does not result in the immediate delisting of the Company’s American Depositary Shares (“ ADSs ”), and the ADSs will continue to trade uninterrupted under the symbol ...
According to consumer-based reporting, LULUTOX Detox Tea is a herbal-based caffeine-free tea supplement that falls under the category of digestive wellness and daily detox products. It is also ...
In seeking FDA approval to bring its innovative Re-Tain® product to market, ImmuCell received Complete Letters from the FDA for four of the five Technical Sections required for NADA approval. It ...
TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has increased the size of its private placement ...
Clinicians at Desert Hope note that relapse often begins mentally before any physical return to substance use occurs. Recognizing the warning signs early and reaching out for help can be critical for ...
Throughout 2025, Clearmind achieved critical milestones in its FDA-approved Phase I/IIa clinical trial for CMND-100, a proprietary non-hallucinogenic MEAI-based oral compound designed to address AUD—a ...
The Reverse Stock Split has been approved by the Company’s shareholders and the Company’s board of directors, and is being effectuated primarily to maintain compliance with Nasdaq Marketplace Rule ...
The Company expects to issue an initial $15.0 million principal amount of notes at closing with the option to fund up to an additional $35.0 million principal amount in one or more tranches subject to ...
Year End 2025 – an increase of $150k offset by recognized revenue of $83k, resulting in $276k compared to $209k as at August 31, 2025 and 2024, respectively. Q1 2026 – increase of $225k, offset by ...
The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline. Moody's affirmed Teva's B1a rating and revised Teva's outlook to positive ...
The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, would like to provide an ...
Three directors purchased a total of 179,737 shares and 179,737 warrants with an average purchase price of $1.224. Dr. Smith has invested in all of MAIA’s funding rounds since the Company’s inception ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback